Introducing Tailored Covalency®

Traditional oral small molecule drugs are convenient, but often have side effects because they may not be selective.

Injectable antibody drugs are highly specific therapies, but an injection is not convenient for the patient.

What if you could have the best of both worlds?

Principia’s novel approach to drug development combines the dosing convenience of a small molecule drug with characteristics of an antibody. Our drugs are designed to be effective, potent, selective, durable and safer than traditional small molecule drugs.

Learn More

A pipeline of differentiated drug candidates that may offer superior safety and efficacy

Phase 1
Phase 2
PRN1008: BTK inhibitor / Pemphigus Vulgaris
PRN1008: BTK inhibitor / Second Indication
PRN1371: FGFR inhibitor / multiple cancers
BTK inhibitor: IO / Solid tumors
IL-17 Pathway inhibitor: Autoimmune / Inflammatory
Immunoproteasome: Autoimmune / Inflammatory